




[도1]




[도2]





[圖3]





[圖4]




[도5]




[도6]




[도7]




[도8]




[도9]




[도10]




[도11]




[圖12]




[圖13]




[圖14]




[圖15]




[圖16]




[圖17]




[도18]




[도19]




[圖20]



[圖21]




[도22]




[도23]


Enzyme complex synergistic effect
(TIM + ALD + FBP)




[도24a]




[도24b]




[도 25]



[도26a]




[도26b]




[도27a]


hGH Unistac



[도27b]


hGH E2-Unistac

[도28a]




[도28b]

Sample		Band intensity	Relative intensity
UniStac mix	+	37479.0	1.16
	-	32150.1	1




WO 2021/107660


[도29a]




Unistac type-1





[도 29b]




Unistac type-2



[도 29c]

**Unistac type-3**

[도30]



Plasma Concentration-time Profiles of Test Substance in SD Rats (N=3).

- OGB1 : Di-Ub-Albumin
- OGB3 : Human serum albumin


Summary of Pharmacokinetics Parameter

Group / Dose (mg/kg)		AUC ₀₋₂₄ (ng·hr/mL)	C _{max} (ng/mL)	T _{max} (hr)	t _{1/2} (hr)
G2 OGB1:0.833	Mean	282,470.33 *	7,769.81 *	16	23.73
	S.D	35,191.94	1,597.53	6.9	3.35
	N	3	3	3	3
G3 OGB3:1	Mean	155,737.74	3,855.00	20	23.01
	S.D	1,909.85	189.59	6.9	6.59
	N	3	3	3	3


Significantly different from Group 3 by Aspin-Welch t-test: * p<0.05.

[도31]


[IgGk(SP)-Ub(A)-Hinge(IgG1)-Fc(IgG1)]



[도32]




[도33]




- SDS-PAGE (Non-Reducing)
- Westernblot (Human IgG Fc(HRP)
Cat. No : Ab99823, Lot. No : GR3286554-1)
- In-house gel (10%)
- Sample Buffer (CUREBIO)


[도34]




[도35]




[도36]




[도37]




[도38]




[도39]




[도40]




[도41]




[도42]




[도43]




[도44]




[도45]




[도46]




[도47]



[도48]



[도49]




Reducing


M	LS	FT	W	Rre E1 (25 %)	Main Elution	Gradient elution (35 ~ 50 %)	S1	S2	CIP
250									
130									
100									
70									
55									
35									
25									

←C-193


[도52]




[도53]



[도54]




[도55]



[도56]

D-192	C-193	C-192
공여체 단백질	UniStac 단백질	HSA-based 수용체 단백질을 사용한 융합단백질
		

[도57]



[도58]

